arrow
İ

İlknur Deliktaş Onur

university of health sciences turkey
H指数:4
被引数:63

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Real-world outcomes of second-line therapy in advanced thymic carcinoma: a multicenter Turkish Oncology Group (TOG) study

晚期胸腺癌二线治疗的实际疗效:一项多中心土耳其肿瘤学组(TOG)研究

2026-08-270
OA
Integrated Prognostic Stratification After Perioperative FLOT in Gastric and Gastroesophageal Junction Adenocarcinoma: A Multicenter Real-World Study
2026-08-150
OAAI
Impact of adjuvant endocrine therapy on disease-free survival in early triple-positive breast cancer: a multicenter retrospective cohort study of the Turkish oncology group

三阴性乳腺癌患者辅助内分泌治疗对无病生存期的影响:土耳其肿瘤学组的回顾性多中心队列研究

2026-08-030
OA
Real-World 30-Day Mortality After the Last Dose of Immune Checkpoint Inhibitors: A Multicenter Retrospective Cohort Study in Turkey

土耳其多中心回顾性队列研究:接受免疫检查点抑制剂最后一剂治疗后30天的实际死亡率

2026-06-060
OA
Prognostic value of nutritional and inflammation-based scores in advanced soft tissue sarcoma treated with trabectedin: a multicenter study

晚期软组织肉瘤接受曲贝替定治疗后营养和炎症评分的预后价值:一项多中心研究

2026-04-230
OA
Clinicopathological Predictors of Pathological Complete Response in HER2-Positive Breast Cancer Treated with Pertuzumab-Based Neoadjuvant Therapy: A Multicenter Real-World Study

人表皮生长因子受体2阳性乳腺癌接受帕妥珠单抗为基础的新辅助治疗后病理完全缓解的临床病理预测因素:一项多中心真实世界研究

2026-04-150
OA
The effect of switching from ribociclib to palbociclib due to toxicity in hormone receptor-positive, HER2-negative metastatic breast cancer: a real-world, multicenter, retrospective study

因毒性作用将ribociclib换用palbociclib对激素受体阳性、HER2阴性转移性乳腺癌的影响:一项真实世界、多中心、回顾性研究

2026-03-260
OAAI
Real-world effectiveness of total neoadjuvant therapy in locally advanced rectal cancer: a multicenter retrospective study

局部晚期直肠癌中总新辅助疗法的真实世界有效性:一项多中心回顾性研究

2026-03-230
OAAI
Real-world outcomes of trastuzumab deruxtecan in patients with HER2+ metastatic breast cancer: Turkish oncology group multicenter study

曲妥珠单抗德鲁替康在HER2+转移性乳腺癌患者中的真实世界疗效:土耳其肿瘤学组多中心研究

2026-03-130
PRE
Health-related quality of life and psychosocial outcomes in long-term survivors treated with immune checkpoint inhibitors: a nationwide multicenter study

与健康相关的生活质量和免疫检查点抑制剂治疗长期存活者的心理社会结局:一项全国性多中心研究

2025-12-100
OA
Survival outcomes and recurrence patterns of early-stage HER2-positive breast cancer patients on adjuvant T-DM1 treatment: Turkish Oncology Group (TOG) Study

早期HER2阳性乳腺癌患者接受辅助T-DM1治疗的生存结局与复发模式:土耳其肿瘤学组(TOG)研究

2025-12-010
PRE
Efficacy of Anti-VEGF and Anti-EGFRs in Microsatellite Instable (MSI-H) Metastatic Colorectal Cancer in a Turkish Oncology Group (TOG) Cohort Study

抗VEGF和抗EGFRs在微卫星不稳定(MSI-H)转移性结直肠癌中的疗效:土耳其肿瘤学组(TOG)队列研究

2025-11-180
OAAI
Impact of sarcopenia on paclitaxel-induced peripheral neuropathy in early-stage breast cancer: a prospective observational study (the neuro-sarc study)

肌少症对早期乳腺癌患者紫杉醇诱导的周围神经病变的影响:一项前瞻性观察研究(神经-肌少症研究)

2025-11-140
PRE
Prognostic Factors in High Grade Osteosarcoma Patients Who Received Neoadjuvant Therapy and Subsequently Underwent Surgery: Data from the Turkish Oncology Group
2025-03-170
OAAI